Search results
Showing 856 to 870 of 7711 results
NICE quick guide - moving between hospital and home, including care homes
A quick guide for practitioners supporting people growing older with learning disabilities.
A quick guide to promoting positive mental wellbeing for older people
Promoting wellbeing and positive identity for a child or young person who is looked after
A quick guide for social workers and social care practitioners The events and experiences that resulted in a child or young person becoming looked...
NICE's quick guide on recognising and preventing delirium
A quick guide to recognising and responding to domestic violence and abuse
A quick guide for registered managers of mental health services for young people
Supporting people who provide unpaid care for adults with health or social care needs
A quick guide for social care practitioners Good quality, consistent support helps the health, wellbeing and resilience of adult carers. Carers are...
A guide to intermediate care services that provide support for a short time to help you recover and increase your independence
A quick guide for people using adult social care services.
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA966
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA969
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.